Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Tesamorelin? Benefits, Research & Safety
An FDA-approved growth hormone releasing hormone analogue used to reduce excess abdominal fat in HIV patients with lipodystrophy.
Also known as:
Egrifta
TH9507
Growth Hormone Releasing Factor
UK summary: FDA-approved in the US (Egrifta) for HIV-associated lipodystrophy with reasonable human evidence base for that specific indication. Not currently a UK-licensed medicine. Prohibited at all times under WADA S2 for athletes.
Quick Facts
Category
Hormonal & Endocrine
Half-Life
26-38 minutes (as GHRH analogue)
UK Status
Not approved. Not available on NHS. May be accessible through specialist channels.
EU Status
Not approved by EMA. Application was withdrawn.
Overview
Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH, also known as growth hormone releasing factor or GRF). It consists of the 44-amino acid sequence of human GHRH with an added trans-3-hexenoic acid group to improve stability.
Tesamorelin was developed by Theratechnologies and is marketed under the brand name Egrifta. It received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a metabolic complication associated with HIV infection and its treatment.
Unlike direct growth hormone administration, tesamorelin stimulates the body's own pituitary gland to produce and secrete growth hormone. This maintains the physiological pulsatile pattern of GH release and may have advantages in terms of the body's normal feedback mechanisms.
Tesamorelin has attracted interest beyond its approved indication for its potential anti-ageing and body composition effects. However, use outside approved indications carries risks and lacks the same level of evidence for safety and efficacy.
The medication is administered by daily subcutaneous injection and requires ongoing treatment to maintain effects. Upon discontinuation, fat typically returns to baseline levels.
Evidence standards summary
Tesamorelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
BModerate human evidenceOverall grade against our evidence grading methodology.
FDA-approved in the US (Egrifta) for HIV-associated lipodystrophy with reasonable human evidence base for that specific indication. Not currently a UK-licensed medicine. Prohibited at all times under WADA S2 for athletes.
02Human evidence grade
BModerate human evidenceStrength of evidence from published human trials.
03Preclinical evidence grade
BModerate human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not approved. Not available on NHS. May be accessible through specialist channels.
- EU: Not approved by EMA. Application was withdrawn.
- Notes: Tesamorelin (Egrifta) is FDA-approved in the US for HIV lipodystrophy. Not approved in UK or EU. Off-label use for anti-ageing or body composition is not supported by approved labeling.
05Approved medical uses
- HIV-associated lipodystrophy (FDA-approved as Egrifta in the US; not MHRA-licensed in the UK).
06Unapproved / promotional claims
- Targeted visceral-fat reduction for healthy adults.
- Anti-ageing growth-hormone restoration.
- Cognitive-decline reversal in older adults.
- Body-recomposition enhancement for bodybuilders.
07Common internet claims
- Marketed as an off-label fat-loss injection for cosmetic visceral-fat reduction.
- Sold by private 'anti-ageing' clinics as a GHRH analogue alternative to HGH.
- Promoted in bodybuilding stacks alongside testosterone, HGH, and insulin.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved for HIV lipodystrophy” | B | Yes | Moderate | Egrifta is FDA-approved for HIV-associated visceral lipodystrophy; this is not the same as UK MHRA approval, and it is not on the NHS. |
| “Targets visceral fat in healthy adults” | C | Limited | High | Outcome data are largely from the HIV-lipodystrophy population; generalising to healthy adults is not supported. |
| “Permitted in sport since it's a 'GHRH analogue'” | E | No | High | Prohibited at all times under WADA S2. |
| “Safer alternative to growth hormone” | E | No | High | Comparative-safety claims need comparative trials in the relevant population. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Hyperglycaemia and worsened insulin resistance with sustained use.
- Joint pain, peripheral oedema, carpal tunnel symptoms (GH-axis side effects).
- Injection-site reactions.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not approved. Not available on NHS. May be accessible through specialist channels.
14EU legal position
Not approved by EMA. Application was withdrawn.
15What this page cannot tell you
- Whether a UK-purchased compounded tesamorelin contains the labelled peptide at the labelled concentration.
- Whether off-label cosmetic-fat-loss use carries the same safety profile as the licensed HIV-lipodystrophy indication.
- Long-term oncologic risk in healthy adults with no diagnosed deficiency.
- What the WADA in-competition exposure looks like — GH secretagogues are class-prohibited (S2).
16Last reviewed
17Citation quality score
BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- No Phase 3 trials in non-HIV populations for cosmetic visceral-fat loss.
- Long-term oncologic surveillance in non-HIV populations absent.
- Body-composition outcome data in healthy adults limited.
- Combination-stack safety with HGH or insulin uncharacterised.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber for clinically relevant weight reduction.
- GP and endocrinologist review for adult GH deficiency with formal testing.
- Resistance training plus structured aerobic exercise — the only evidence-based body-recomposition stack.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Tesamorelin a licensed UK medicine?
- If I have HIV-associated lipodystrophy, what UK access routes exist?
- If I'm an athlete, what is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
Discovery & History
Tesamorelin was developed by Theratechnologies, a Canadian biopharmaceutical company, in the early 2000s. The peptide was designed as a stabilised analogue of naturally occurring GHRH with improved pharmacokinetic properties.
The development focus was on HIV-associated lipodystrophy, a syndrome characterised by abnormal fat distribution—particularly visceral fat accumulation—seen in many HIV-positive patients, often associated with antiretroviral therapy.
Clinical development included multiple Phase III trials demonstrating significant reductions in trunk fat with tesamorelin treatment compared to placebo. Studies showed meaningful reductions in visceral adipose tissue measured by CT scan.
In November 2010, the FDA approved tesamorelin (Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This approval made it the first medication specifically approved for this indication.
The EMA did not approve tesamorelin, citing concerns about the clinical benefit-risk balance for the EU population. Research continues into potential applications in other conditions including cognitive decline in older adults and broader metabolic indications.
Mechanism of Action
Tesamorelin works through specific activation of GHRH receptors on pituitary somatotroph cells:
**GHRH Receptor Activation**
Tesamorelin binds to GHRH receptors (GHRH-R) on the anterior pituitary gland:
- Stimulates synthesis and secretion of growth hormone
- Maintains pulsatile GH release pattern (more physiological than exogenous GH)
- Effect is dependent on functioning pituitary somatotrophs
- Subject to normal feedback regulation by IGF-1 and somatostatin
**Growth Hormone Effects on Fat Metabolism**
Increased GH leads to metabolic changes affecting adipose tissue:
- Stimulation of lipolysis (fat breakdown)
- Preferential reduction of visceral adipose tissue
- Enhanced fatty acid oxidation
- Effects on lipid profiles
**IGF-1 Elevation**
GH stimulation leads to increased IGF-1 production:
- Contributes to metabolic effects
- May have anabolic effects on lean tissue
- Involved in GH feedback regulation
**Stabilisation Chemistry**
The trans-3-hexenoic acid modification:
- Protects against enzymatic degradation
- Improves binding affinity to albumin
- Extends biological activity
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant reduction in visceral adipose tissue (trunk fat)
- 2Modest improvements in trunk fat to limb fat ratio
- 3Improvements in some cardiovascular risk biomarkers
- 4Potential improvement in body image and quality of life
- 5Maintains physiological pulsatile GH release
- 6Research ongoing into cognitive benefits in older adults
Claim vs Evidence
How popular claims about Tesamorelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved for HIV lipodystrophy” | B | Yes | Moderate | Egrifta is FDA-approved for HIV-associated visceral lipodystrophy; this is not the same as UK MHRA approval, and it is not on the NHS. |
| “Targets visceral fat in healthy adults” | C | Limited | High | Outcome data are largely from the HIV-lipodystrophy population; generalising to healthy adults is not supported. |
| “Permitted in sport since it's a 'GHRH analogue'” | E | No | High | Prohibited at all times under WADA S2. |
| “Safer alternative to growth hormone” | E | No | High | Comparative-safety claims need comparative trials in the relevant population. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 2 mg subcutaneous injection daily (approved dose) |
| Frequency | Once daily |
| Duration | Ongoing treatment required; effects reverse upon discontinuation |
| Notes | Tesamorelin (Egrifta) is FDA-approved only for HIV lipodystrophy. Off-label use lacks the same evidence base. Treatment requires ongoing administration. Should be prescribed and monitored by a physician. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (approved route)
| Half-Life | Stability |
|---|---|
| 26-38 minutes (as GHRH analogue) | Commercial product has defined stability; requires refrigeration |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (most common)
- Arthralgia (joint pain)
- Peripheral oedema
- Myalgia (muscle pain)
- Pruritus (itching)
- Paraesthesia
Rare Risks & Concerns
- Fluid retention syndromes
- Glucose intolerance or worsening diabetes
- Hypersensitivity reactions
- Potential effects on tumour growth (theoretical)
- Carpal tunnel syndrome
Contraindications
- Active malignancy
- Pregnancy and breastfeeding (Category X)
- Hypersensitivity to tesamorelin or mannitol
- Disruption of hypothalamic-pituitary axis (head trauma, surgery, etc.)
- Pituitary tumour or pituitary surgery
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved. Not available on NHS. May be accessible through specialist channels.
🇪🇺 European Union
Not approved by EMA. Application was withdrawn.
Tesamorelin (Egrifta) is FDA-approved in the US for HIV lipodystrophy. Not approved in UK or EU. Off-label use for anti-ageing or body composition is not supported by approved labeling.
Clinical Studies Summary
Tesamorelin Phase 3 HIV Lipodystrophy Trials
Pivotal trials demonstrating significant reduction in trunk fat in HIV patients with lipodystrophy.
Endocrine and HIV journalsView on PubMed
Tesamorelin and Cognitive Function
Research investigating potential cognitive benefits of tesamorelin in older adults.
Neurology and ageing journalsView on PubMed
Looking for Tesamorelin?
Source research-grade Tesamorelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Tesamorelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Tesamorelin a licensed UK medicine?
- If I have HIV-associated lipodystrophy, what UK access routes exist?
- If I'm an athlete, what is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
AOD-9604
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
Learn moreCJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreSermorelin
A truncated form of natural GHRH that was the first GHRH analogue approved for clinical use, used for GH deficiency diagnosis and treatment.
Learn more